Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Pharming Group has a consensus price target of $33.5 based on the ratings of 2 analysts. The high is $37 issued by HC Wainwright & Co. on October 24, 2024. The low is $30 issued by Oppenheimer on October 28, 2024. The 3 most-recent analyst ratings were released by Oppenheimer, HC Wainwright & Co., and HC Wainwright & Co. on October 28, 2024, October 24, 2024, and October 15, 2024, respectively. With an average price target of $34.67 between Oppenheimer, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 351.39% upside for Pharming Group from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Pharming (NASDAQ:PHAR) was reported by Oppenheimer on October 28, 2024. The analyst firm set a price target for $30.00 expecting PHAR to rise to within 12 months (a possible 269.46% upside). 8 analyst firms have reported ratings in the last year.
The latest analyst rating for Pharming (NASDAQ:PHAR) was provided by Oppenheimer, and Pharming maintained their outperform rating.
There is no last upgrade for Pharming
There is no last downgrade for Pharming.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pharming, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pharming was filed on October 28, 2024 so you should expect the next rating to be made available sometime around October 28, 2025.
While ratings are subjective and will change, the latest Pharming (PHAR) rating was a maintained with a price target of $31.00 to $30.00. The current price Pharming (PHAR) is trading at is $8.12, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.